1. No category

Departamento de Patentes e Información Tecnológica
Unidad de Información Tecnológica
NANOFÁRMACOS
69 Resultados
Solicitudes de Patente publicadas a nivel mundial en los últimos 30 dias.
Datos actualizados a 22/02/2015 [15:19:00]
STEREOISOMER PEPTIDES, THEIR POLYMER CONJUGATES, THEIR ENCAPSULATION INTO NANOPARTICLES, AND
USES THEREOF FOR THE TREATMENT OF DISEASES CAUSED BY ABNORMAL ANGIOGENESIS.
Nº publicación US2015050351A1 19/02/2015
GONZALEZ LUCIA IRENE¿[US]
Solicitantes
This invention discloses the creation of a novel single ligand-targeted multi-stereoisomer peptide-polymer conjugate compounds
Resumen
comprising a group of different synthetic and chemically modified stereoisomer peptides that have been conjugated to a
biocompatible polymer carrying a peptide ligand for targeted delivery and/or encapsulated in ligand targeted polymer
nanoparticles. The unique physicochemical properties of the stereoisomer peptides provide therapeutic compounds with ideal
biopharmaceutical properties. The stereoisomer peptides carried by the polymer are delivered to cells or tissues to inhibit,
suppress, block, antagonize or disrupt, simultaneously and independently, the functional domain of different disease causing
proteins. Therefore the compounds are novel therapeutics for the treatment of abnormal angiogenesis and inflammation which are
the hall mark of most human diseases including but not limited to all cancers, metastasis, eye retinopathies, cardiovascular, brain,
and neurodegenerative disorders, diabetes, and diseases caused by infectious microorganisms including virus, bacteria, fungi, and
parasites.
SYSTEMS AND METHODS FOR PARTICLE RADIATION ENHANCED DELIVERY OF THERAPY
Nº publicación US2015050349A1 19/02/2015
UNIV LOMA LINDA MED¿[US]
Solicitantes
Systems and methods for enhancing the selective targeting of agents for preferential action at a target with reduced action with
Resumen
healthy tissue distal the target tissue. One or more agents can be combined with nano scale structures/particles for delivery to the
target tissue. Appropriate bombardment with accelerated particle radiation, such as proton radiation, induces the release of the
agents at the target site. Nano carriers can be combined with therapeutic and/or imaging enhancement agents. Imaging of the
target tissue can provide a verification of the delivered dose of particle radiation. Nanocarriers can be provided with an outer shell
selected for biocompatibility and durability in the in vivo environment and further selected to provide a feedback mechanism in
the treatment environment to accelerate the release of the agent and reduce a total radiation dose needed for that release.
COMPOSITIONS AND METHODS FOR TREATING INSULIN RESISTANCE AND DIABETES MELLITUS
Nº publicación US2015050346A1 19/02/2015
REVALESIO CORP¿[US]
Solicitantes
Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of
Resumen
charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular
membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating diabetes
and diabetes-associated conditions or disorders (e.g., insulin resistance), or symptoms thereof. Provided are
electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents.
Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory
responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane
receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap
junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the
electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions.
Alertas Tecnológicas
- 1 de 31 -
NANOFÁRMACOS
Departamento de Patentes e Información Tecnológica
Unidad de Información Tecnológica
COMPOSITIONS AND METHODS FOR UPREGULATING HIPPOCAMPAL PLASTICITY AND HIPPOCAMPUS-DEPENDENT
LEARNING AND MEMORY
Nº publicación US2015050344A1 19/02/2015
REVALESIO CORP¿[US]
Solicitantes
Provided are methods for enhancing hippocampal plasticity and
Resumen
hippocampal-mediated learning and memory, and/or enhancing the
synaptic maturation of neurons, and/or optimizing or enhancing
neuronal synaptic transmission, and/or enhancing intracellular oxygen
delivery or utilization, and/or enhancing ATP synthesis, comprising
administration, to a subject in need thereof of a sufficient amount over
a sufficient time, of an ionic aqueous solution of charge-stabilized
oxygen-containing nanostructures (e.g., nanobubbles) having an
average diameter of less than 100 nm (e.g., in at least one subject
group selected from but not limited to normal subjects, subjects
recovering from neurological trauma (e.g., accidents or injury to the
brain, stroke, oxygen deprivation, drowning, and asphyxia), and
subjects with learning disorders (e.g., dyslexia, dyscalculia,
dysgraphia,
dyspraxia
(sensory
integration
disorder),
dysphasia/aphasia, auditory processing disorder, non-verbal learning
disorder, visual processing disorder, and attention deficit disorder
(ADD)).
METHODS OF WOUND CARE AND TREATMENT
Nº publicación US2015050343A1 19/02/2015
REVALESIO CORP¿[US]
Solicitantes
Provided are electrokinetically-altered fluids (e.g., gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of
Resumen
charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular
membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating a wound
to a surface tissue or a symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include
electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents.
Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory
responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane
receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap
junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the
electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions.
Alertas Tecnológicas
- 2 de 31 -
NANOFÁRMACOS
Departamento de Patentes e Información Tecnológica
Unidad de Información Tecnológica
NANOEMULSION VACCINES
Nº publicación US2015050318A1 19/02/2015
UNIV MICHIGAN¿[US]
Solicitantes
The present invention provides methods and compositions for the
Resumen
stimulation of immune responses. Specifically, the present invention
provides immunogenic compositions and methods of using the same
to induce immune responses (e.g., immunity (e.g., protective
immunity) against Hepatitis B virus (HBV) and/or against one or a
plurality of pathogens (e.g., vaccinia virus, H5N1 influenza virus,
Bacillus anthracis, C. botulinum, Y. pestis, Hepatits B, and/or HIV,
etc.)) in a subject. Compositions and methods of the present invention
find use in, among other things, clinical (e.g. therapeutic and
preventative medicine (e.g., vaccination)) and research applications.
Alertas Tecnológicas
- 3 de 31 -
NANOFÁRMACOS
Departamento de Patentes e Información Tecnológica
Unidad de Información Tecnológica
ULTRAFINE NANOPARTICLES AS MULTIMODAL CONTRAST AGENT
Nº publicación US2015050217A1 19/02/2015
UNIV CLAUDE BERNARD LYON¿[FR]
Solicitantes
NANO H¿[FR]
CENTRE NAT RECH SCIENT¿[FR]
UNIV JOSEPH FOURIER¿[FR]
UNIV CLAUDE BERNARD LYON¿[FR]
The invention relates to a novel use of ultrafine nanoparticles, which
Resumen
are of use as a diagnostic, therapeutic or theranostic agent,
characterized by the mode of administration thereof via the airways.
The invention is also directed towards the uses which follow from this
new mode of administration, in particular for imaging the lungs, and
the diagnosis or prognosis of lung diseases. In the therapeutic field,
the uses envisaged are those of radiosensitizing or radioactive agents
for radiotherapy (and optionally curietherapy), for neutron therapy,
and of agents for PDT (photodynamic therapy), in particular for
treating lung tumours.
A NOVEL PLGA-MODIFIED POLYETHYLENIMINE SELF-ASSEMBLY NANOTECHNOLOGY FOR NUCLEIC ACID AND
DRUG DELIVERY
Nº publicación WO2015023775A1 19/02/2015
BAYLOR COLLEGE MEDICINE¿[US]
Solicitantes
Embodiments of the invention concern copolymers and nanoparticles for use as delivery agents for one or more agents for therapy
Resumen
for a medical condition of humans and animals. Some of embodiments of the invention provide new reagents for biomedical
research in cell culture, animal models and plants, for example. The copolymers comprise PLGA and PEI and, in some
embodiments, also comprise l-(3-aminopropyl)-4-methylpiperazine (APMP), Fc binding peptide and/or antibody. In certain
embodiments, APMP-PLGA-PEI, Fc binding peptide/antibody-PLGA-PEI or Fc binding peptide/antibody-APMP-PLGA-PEI
nanoparticles comprising one or more therapeutic agents are delivered to an individual in need thereof or used for biomedical
research in cell cultures, animal models and plants.
NANOZYMES, METHODS OF MAKING NANOZYMES, AND METHODS OF USING NANOZYMES
Nº publicación WO2015023715A1 19/02/2015
UNIV FLORIDA¿[US]
Solicitantes
Embodiments of the present disclosure provide for nanozymes having a core/shell nanoparticle, hollow nanozymes, hollow
Resumen
nanozymes including a therapeutic agent, methods of making nanozymes, methods of using nanozymes, and the like.
Alertas Tecnológicas
- 4 de 31 -
NANOFÁRMACOS
Departamento de Patentes e Información Tecnológica
Unidad de Información Tecnológica
METHODS FOR PRODUCING OPTIMAL STABLE NANOEMULSIONS AND FORMULATIONS OBTAINED THEREFROM
Nº publicación US2015051298A1 19/02/2015
MCCLEMENTS DAVID J¿[US]
Solicitantes
SABERI AMIR H¿[US]
CHANG YUHUA¿[US]
MCLANDSBOROUGH LYNNE¿[US]
A method for producing stable nanoemulsions having a desired droplet size and functional properties tailored for use in a specific
Resumen
application (which is referred to as substantially optimizing composition) that includes selecting an aqueous phase
the aqueous phase comprising at least one ingredient from water, surfactant, co-surfactant and co-solvent, the aqueous phase
being selected such that a stable nanoemulsions having a desired droplet size and functional properties tailored for use in a
specific application is obtained, and selecting an organic phase comprising at least two ingredients from lipophilic component, oil,
surfactant, co-surfactant and cosolvent, the organic phase being selected such that a stable nanoemulsions having a desired droplet
size and functional properties tailored for use in a specific application is obtained, a nanoemulsion being formed when the organic
phase is mixed with the aqueous phase.
DRUG DELIVERY CONJUGATE CAPABLE OF CONTROLLED RELEASE, AND USE THEREOF
Nº publicación US2015051269A1 19/02/2015
POSTECH ACAD IND FOUND¿[KR]
Solicitantes
KYUNGPOOK NAT UNIV IND ACAD¿[KR]
The present invention relates to a hydrophobic drug delivery
Resumen
conjugate, to which cyclodextrin, poly(maleic anhydride), and a
hydrophobic drug are bonded, and to a pharmaceutical composition
comprising the hydrophobic drug delivery conjugate as an active
ingredient. The hydrophobic drug delivery conjugate according to the
present invention can effectively control the release rate and the
delivery rate of a hydrophobic drug by regulating the physicochemical
bonding and/or composition of the cyclodextrin, poly(maleic
anhydride), and hydrophobic drug, and can also increase the effect of
the drug by significantly increasing the solubility of the hydrophobic
drug. Further, the present invention can enable the type of the
hydrophobic drug to be varied, as well as a peptide having target
directivity to be introduced into a surface of the conjugate, such that
the present invention can be applied to the treatment of various
diseases in addition to cancer treatment.
Alertas Tecnológicas
- 5 de 31 -
NANOFÁRMACOS
Departamento de Patentes e Información Tecnológica
Unidad de Información Tecnológica
DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE
TRANSFER IN VIVO
Nº publicación US2015051265A1 19/02/2015
ENGENE INC¿[CA]
Solicitantes
Provided herein is chitosan dually derivatized with arginine and
Resumen
g l u c o n i c
a c i d
and methods of making and using the same, e.g., for gene delivery in
vivo.
PROCESS FOR PRODUCING NANOPARTICLES LADEN WITH ACTIVE INGREDIENT
Nº publicación US2015051181A1 19/02/2015
MERCK PATENT GMBH¿[DE]
Solicitantes
The present invention relates to a new process for producing
Resumen
nanoparticles laden with active ingredients, and to the use thereof as
medicaments. The process for producing nanoparticles comprises the
steps (a) dissolution of at least one active ingredient and at least one
polymer in an organic solvent, (b) mixing the solution prepared in step
(a) with an aqueous phase, (c) evaporating the organic solvent, (d)
purifying the nanoparticles laden with active ingredient obtained in
step (c) by means of dialysis against aqueous dialysis solution
containing the same active ingredient.
Alertas Tecnológicas
- 6 de 31 -
NANOFÁRMACOS
Departamento de Patentes e Información Tecnológica
Unidad de Información Tecnológica
NANOPARTICLE ISOFLAVONE COMPOSITIONS & METHODS OF MAKING AND USING THE SAME
Nº publicación US2015050357A1 19/02/2015
HUMANETICS CORP¿[US]
Solicitantes
The present invention is directed to formulations of genistein and
Resumen
methods for making and using the same. In particular embodiments,
the formulations described herein include suspension formulations of
nanoparticulate genistein.
NANOPARTICLE COMPRISING RAPAMYCIN AND ALBUMIN AS ANTICANCER AGENT
Nº publicación US2015050356A1 19/02/2015
ABRAXIS BIOSCIENCE LLC¿[US]
Solicitantes
The present invention features methods for treating, stabilizing,
Resumen
preventing, and/or delaying cancer by administering nanoparticles that
comprise rapamycin or a derivative thereof. The invention also
provides compositions (e.g., unit dosage forms) comprising
nanoparticles that comprise a carrier protein and rapamycin or a
derivative thereof. The invention further provides combination therapy
methods of treating cancer comprising administering to an individual
an effective amount of nanoparticles that comprise rapamycin or a
derivative thereof and a second therapy.
Alertas Tecnológicas
- 7 de 31 -
NANOFÁRMACOS
Departamento de Patentes e Información Tecnológica
Unidad de Información Tecnológica
ULTRAFINE NANOPARTICLES AS MULTIMODAL CONTRAST AGENT
Nº publicación EP2836237A1 18/02/2015
UNIVERSITÉ CLAUDE BERNARD LYON I¿[FR]
Solicitantes
NANO H¿[FR]
CENTRE NAT RECH SCIENT¿[FR]
UNIV JOSEPH FOURIER¿[FR]
The invention relates to a novel use of ultrafine nanoparticles, which
Resumen
are of use as a diagnostic, therapeutic or theranostic agent,
characterized by the mode of administration thereof via the airways.
The invention is also directed towards the uses which follow from this
new mode of administration, in particular for imaging the lungs, and
the diagnosis or prognosis of lung diseases. In the therapeutic field,
the uses envisaged are those of radiosensitizing or radioactive agents
for radiotherapy (and optionally curietherapy), for neutron therapy,
and of agents for PDT (photodynamic therapy), in particular for
treating lung tumours.
Biocompatible polymer nanocapsules with quantum dots, method of manufacturing them and their application
Nº publicación PL407664A1 16/02/2015
POLITECHNIKA WROCLAWSKA¿[PL]
Solicitantes
Alertas Tecnológicas
- 8 de 31 -
NANOFÁRMACOS
Departamento de Patentes e Información Tecnológica
Unidad de Información Tecnológica
SUSTAINED DELIVERY OF THERAPEUTIC AGENTS TO AN EYE COMPARTMENT
Nº publicación US2015044270A1 12/02/2015
UNIV JOHNS HOPKINS¿[US]
Solicitantes
Compositions and methods for treating eye disorders by administering
Resumen
a drug delivery system into an eye compartment of the patient,
wherein the drug delivery system contains a particle containing a core
a coating associated with the particle, wherein the wherein the coating
is covalently or non-covalently associated with the particle and
presents a hydrophilic region to the environment around the particle
and a therapeutic agent are disclosed. The eye compartment can
exhibit reduced inflammation or IOP after administration of the drug
delivery systems to a patient than if a drug delivery system including
an uncoated particle were administered to the patient.
NANOPARTICLES OF A METAL AND A NUCLEOBASE
Nº publicación US2015045450A1 12/02/2015
CERION LLC¿[US]
Solicitantes
A process for making nanoparticles of biocompatible materials is described, wherein an aqueous reaction mixture comprising a
Resumen
metal ion, a nucleobase, an oxidant, and water, is provided along with temperature conditions to directly form within the reaction
mixture, a stable dispersion of nanoparticles. Biocompatible nanoparticles comprised of cerium or iron as the metal ion, and a
purine and/or a pyrimidine as the nucleobase, are described.
Alertas Tecnológicas
- 9 de 31 -
NANOFÁRMACOS
Departamento de Patentes e Información Tecnológica
Unidad de Información Tecnológica
REVERSIBLY CROSSLINKED MICELLE SYSTEMS
Nº publicación US2015045419A1 12/02/2015
LAM KIT S¿[US]
Solicitantes
LI YUANPEI¿[US]
UNIV CALIFORNIA¿[US]
The present invention provides amphiphilic telodendrimers that
Resumen
aggregate to form nanocarriers characterized by a hydrophobic core
and a hydrophilic exterior. The nanocarrier core may include
amphiphilic functionality such as cholic acid or cholic acid
derivatives, and the exterior may include branched or linear
poly(ethylene glycol) segments. Nanocarrier cargo such as
hydrophobic drugs and other materials may be sequester in the core
via non-covalent means or may be covalently bound to the
telodendrimer building blocks. Telodendrimer structure may be
tailored to alter loading properties, interactions with materials such as
biological membranes, and other characteristics.
Oxygenated Antimicrobial Topical Composition
Nº publicación US2015044299A1 12/02/2015
ESTY JOANNA M¿[US]
Solicitantes
The present invention relates to an antimicrobial topical composition and process for making such composition. The composition
Resumen
comprises of ionic silver, silver nanoparticles, and oxygen, combined within a gel medium and applied topically. The composition
optimizes the ionic silver and silver nanoparticle ratio providing for sufficient ionic silver to be delivered as an immediate
antimicrobial agent, and sufficient nanoparticle silver to provide time release for conversion to silver ions for continuing
antimicrobial effectiveness.
NANOPARTICLES AND NANOPARTICLE COMPOSITION, AND METHOD FOR PRODUCING NANOPARTICLES AND
NONPARTICLE COMPOSITION
Nº publicación WO2015020139A1 12/02/2015
UNIV KINKI¿[JP]
Solicitantes
OTSUKA PHARMA CO LTD¿[JP]
The present invention relates to a nanoparticle composition obtained by a method characterized in dissolving a sparingly-soluble
Resumen
compound in water or the like under high temperature and high pressure, and crushing the suspension or the like containing
uniform crystals obtained by cooling the obtained solution.
NANOPARTICLES LEVERAGE BIOLOGICAL MEMBRANES TO TARGET PATHOGENS FOR DISEASE TREATMENT AND
DIAGNOSIS
Nº publicación WO2015021390A2 12/02/2015
UNIV CALIFORNIA¿[US]
Solicitantes
Provided are methods, combinations and pharmaceutical compositions for treating or preventing an infection in a subject using a
Resumen
nanoparticle comprising a) an inner core comprising a non-cellular material, and b) an outer surface comprising a cellular
membrane configured for adhesion of a pathogen that causes said infection. Exemplary infection includes infection caused by a
virus, bacterium, fungus, or protozoan.
Alertas Tecnológicas
- 10 de 31 -
NANOFÁRMACOS
Departamento de Patentes e Información Tecnológica
Unidad de Información Tecnológica
DELIVERY SYSTEM FOR ACTIVE AGENTS
Nº publicación WO2015019211A1 12/02/2015
KIMBERLY CLARK CO¿[US]
Solicitantes
A delivery system containing an active agent within a polymeric material formed from a thermoplastic composition is provided.
Resumen
Through selective control over the particular nature of the thermoplastic composition, as well as the manner in which it is formed,
the present inventors have discovered that a porous network can be created that contains a plurality of micropores and nanopores.
The ability to create such a multimodal pore size distribution can allow the delivery rate of an active agent to be tailored for a
particular use.
COMBINATION THERAPY WITH AN ANTI - HYALURONAN AGENT AND A TUMOR - TARGETED TAXANE
Nº publicación EP2833905A1 11/02/2015
HALOZYME INC¿[US]
Solicitantes
Provided herein is combination therapy containing an anti-hyaluronan
Resumen
agent, such as a polymer-conjugated hyaluronan-degrading enzyme,
and a tumor-targeted taxane, and optionally a further
chemotherapeutic agent such as a nucleoside analog. The combination
therapy can be used in methods of treating cancers, and in particular
solid tumor cancers.
Alertas Tecnológicas
- 11 de 31 -
NANOFÁRMACOS
Departamento de Patentes e Información Tecnológica
Unidad de Información Tecnológica
SOFT CHEWABLE PHARMACEUTICAL PRODUCTS
Nº publicación EP2833866A1 11/02/2015
INTERVET INT BV¿[NL]
Solicitantes
A soft chewable pharmaceutical product for delivery of a
Resumen
pharmaceutically acceptable active ingredient to an animal comprising
pamoic acid or a pharmaceutically acceptable salt and a process for
the manufacture of such soft chewable pharmaceutical product.
SOFT CHEWABLE PHARMACEUTICAL PRODUCTS
Nº publicación EP2833867A1 11/02/2015
INTERVET INT BV¿[NL]
Solicitantes
A soft chewable pharmaceutical product for delivery of a
Resumen
pharmaceutically acceptable active ingredient to an animal comprising
pamoic acid or a pharmaceutically acceptable salt and a process for
the manufacture of such soft chewable pharmaceutical product.
Alertas Tecnológicas
- 12 de 31 -
NANOFÁRMACOS
Departamento de Patentes e Información Tecnológica
Unidad de Información Tecnológica
MICROPARTICLES AND NANOPARTICLES MADE UP OF HYDROPHOBIZED POLYSACCHARIDES AND AN
ALPHA-CYCLODEXTRINE
Nº publicación EP2833919A1 11/02/2015
CENTRE NAT RECH SCIENT¿[FR]
Solicitantes
The invention relates to microparticles and nanoparticles made up of
Resumen
hydrophobized polysaccharides and an alpha-cyclodextrine. Said
microparticles and nanoparticles are obtained by means of
self-combining in an aqueous medium. Said hydrophobized
polysaccharide is obtained by grafting alkyl chains of fatty acids via
an acylation reaction. Said microparticles and nanoparticles make up
systems used to encapsulate substances of interest, in particular in the
pharmaceutical field, and to target said substances for therapeutic
purposes.
Alertas Tecnológicas
- 13 de 31 -
NANOFÁRMACOS
Departamento de Patentes e Información Tecnológica
Unidad de Información Tecnológica
Tumour-targeted theranostic
Nº publicación GB2516882A 11/02/2015
UNIV BRADFORD¿[GB]
Solicitantes
UNIV LELAND STANFORD JUNIOR¿[US]
A conjugate comprising a vascular disrupting agent (VDA) which
Resumen
binds to the colechicine binding site of tubulin, a matrix
metalloprotease (MMP) cleavable linker comprising the amino acid
sequence gly-hof-tyr-leu- or arg-ser-cit-gyl-hof-tyr-, a nanoparticle
bearing a magnetic resonance imaging (MRI) contrast agent, and
wherein the conjugate doe not comprise folate. These nanoparticles
are targeted to tumour sites, which may have specific elevated MMP14 activity which cleaves the linker. This single conjugate to
simultaneously deliver a vascular disrupting agent (VDA) and a MRI
contrast agent to a tumour site. The VDA may be a colchicines,
anlagog, combrestatin, phenstatin, podophyllotoxin, steganacin,
amphethinile or stilbene. Consequently, the present invention provides
a cancer "theranostic" which improves therapeutic efficacy whilst
simultaneously reducing dose-limiting systemic toxicities and
provides a tool for rapidly and non-invasively identifying tumour
location, monitoring drug delivery and pharmacodynamics.
NEUROPHILIC NANOPARTICLES
Nº publicación EP2833926A1 11/02/2015
UNIV FLORIDA¿[US]
Solicitantes
Novel liposomal nanoparticle that has been engineered to be
Resumen
particularly useful for the delivery of compounds to cells found in the
peripheral nervous system, and to endothelial cells that form the blood
brain barrier. These nanoparticles are intended to be useful for the
delivery of compounds suitable for therapeutic purposes and imaging
contrast agents that may not otherwise gain access to neuronal axons,
or glial cells regions of the brain. Particularly advantageous for the
purpose of targeting neural cells, endothelial cells of the blood vessels
and epithelial cells of the choroid plexus that serve the brain is the
inclusion, in the nanoparticles of cholesterol that surprisingly
increases the affinity of the nanoparticles for such as Schwann cells,
glial cells, and the like. Image contrast agents, such as those suitable
for use in MRI techniques may also be delivered to neural cells,
including of the peripheral nervous system. These advantageous
liposomal nanoparticles at least comprise a phospholipid, a non-ionic
surfactant, and cholesterol (or a derivative thereof).
Alertas Tecnológicas
- 14 de 31 -
NANOFÁRMACOS
Departamento de Patentes e Información Tecnológica
Unidad de Información Tecnológica
Nanocomposites for encapsulation of cells and method for treating diseases
Nº publicación EP2835644A1 11/02/2015
USSEMBAYEV YERZHAN¿[NL]
Solicitantes
Die vorliegende Erfindung betrifft einen Polymer-Partikel-Komplex,
Resumen
der für die Einkapselung von lebenden Zellen verwendbar ist.
Insbesondere werden (lebende) Zellen mit dem erfindungsgemässen
Polymer-Partikel-Komplex eingekapselt, wobei dabei Krankheiten
spezifisch behandelt werden können.
Tumour-targeted theranostic
Nº publicación WO2015014756A1 05/02/2015
UNIV BRADFORD¿[GB]
Solicitantes
UNIV LELAND STANFORD JUNIOR¿[US]
A conjugate comprising a vascular disrupting agent (VDA) which
Resumen
binds to the colechicine binding site of tubulin, a matrix
metalloprotease (MMP) cleavable linker comprising the amino acid
sequence gly-hof-tyr-leu- or arg-ser-cit-gyl-hof-tyr-, a nanoparticle
bearing a magnetic resonance imaging (MRI) contrast agent, and
wherein the conjugate doe not comprise folate. These nanoparticles
are targeted to tumour sites, which may have specific elevated MMP14 activity which cleaves the linker. This single conjugate to
simultaneously deliver a vascular disrupting agent (VDA) and a MRI
contrast agent to a tumour site. The VDA may be a colchicines,
anlagog, combrestatin, phenstatin, podophyllotoxin, steganacin,
amphethinile or stilbene. Consequently, the present invention provides
a cancer "theranostic" which improves therapeutic efficacy whilst
simultaneously reducing dose-limiting systemic toxicities and
provides a tool for rapidly and non-invasively identifying tumour
location, monitoring drug delivery and pharmacodynamics.
Alertas Tecnológicas
- 15 de 31 -
NANOFÁRMACOS
Departamento de Patentes e Información Tecnológica
Unidad de Información Tecnológica
NANO DELIVERY SYSTEMS
Nº publicación US2015037427A1 05/02/2015
YISSUM RES DEV CO¿[IL]
Solicitantes
The present invention makes use of a unique methodology of double
Resumen
nano- encapsulation for protecting and controlling the release of active
agents, either hydrophobic or hydrophilic, from stable nanoparticles of
opposite characteristics. The protection of the active agent was
achieved by loading the agent to be protected, into nanocarriers, which
were subsequently encapsulated into sub-micron nanoparticles. The
sub-micron nanoparticles formation has been successfully achieved by
the use of novel nano spray techniques.
Functional PLA-PEG copolymers, the nanoparticles thereof, their preparation and use for targeted drug delivery and imaging
Nº publicación US2015037419A1 05/02/2015
SANOFI SA¿[FR]
Solicitantes
The present invention concerns novel functional PEG-PLA containing
Resumen
copolymers, the nanoparticles containing the same, their process of
preparation and their use for site specific targeted drug delivery and
imaging.
Alertas Tecnológicas
- 16 de 31 -
NANOFÁRMACOS
Departamento de Patentes e Información Tecnológica
Unidad de Información Tecnológica
USES OF POROUS NANOSTRUCTURE IN DELIVERY
Nº publicación US2015037249A1 05/02/2015
NVIGEN INC¿[US]
Solicitantes
The present invention relates to methods for delivering at least one
Resumen
agent unto or into a biological sample or a biological subject. The
methods comprise a step of contacting the biological sample or subject
with a payload-carrying nanostructure. The nanostructure can be a
porous low density nanostructure.
METHODS AND APPARATUSES FOR SURFACE FUNCTIONALIZATION AND COATING OF NANOCRYSTALS
Nº publicación US2015038578A1 05/02/2015
NIKOOBAKHT BABAK¿[US]
Solicitantes
The present disclosure describes a method and series of compositions for surface functionalization of nanoparticles that eliminates
Resumen
the possibility of ligand loss in alien environments. In particular, the present disclosure provides method and compositions for
production of highly-stable surface-functionalized nanorods of noble metals for in-vivo applications as well as use in composite
materials.
Alertas Tecnológicas
- 17 de 31 -
NANOFÁRMACOS
Departamento de Patentes e Información Tecnológica
Unidad de Información Tecnológica
COSMETIC TEXTILE FIBER, METHOD FOR OBTAINING IT AND USE THEREOF
Nº publicación US2015035195A1 05/02/2015
NYLSTAR S A¿[ES]
Solicitantes
The present invention describes a polyamide textile fiber comprising
Resumen
conjugated nanoparticles homogeneously dispersed in the fiber,
selected from polyethylene glycol-conjugated platinum nanoparticles,
hyaluronic acid- conjugated gold nanoparticles and mixtures thereof.
The invention also describes how to obtain it as well as its use in a
cosmetic skin treatment as a system for the release of said conjugated
nanoparticles.
GELATIN-BASED NANOPARTICLE COMPLEX FOR TUMOR-TARGETED DELIVERY OF siRNA AND METHOD FOR
PREPARING THE SAME
Nº publicación US2015038690A1 05/02/2015
KOREA INST SCI & TECH¿[KR]
Solicitantes
Disclosed is a gelatin-based nanoparticle complex for tumor-targeted delivery of siRNA for specific gene silencing in tumor cells.
Resumen
The gelatin-based nanoparticle complex includes: poly-siRNA chains whose ends are modified with thiol groups
and thiolated gelatin bound to the poly-siRNA chains through disulfide crosslinking and charge interactions. The gelatin-based
nanoparticle complex is not degraded in the bloodstream and can be efficiently absorbed into tumor cells without cytotoxicity.
The delivered siRNA can effectively silence target gene expression. Also disclosed is a method for preparing the gelatin-based
nanoparticle complex.
DISAGGREGATION OF AGGREGATED NANODIAMOND CLUSTERS
Nº publicación US2015038593A1 05/02/2015
GOGOTSI YURY¿[US]
Solicitantes
MOCHALIN VADYM¿[US]
UNIV DREXEL¿[US]
The present invention is directed to methods of disaggregating
Resumen
nanodiamond clusters, especially those clusters typically produced
from detonation syntheses, the nanodiamond particles and dispersions
produced from these disaggregation processes, and compositions
derived from these nanodiamond particles and dispersions.
Alertas Tecnológicas
- 18 de 31 -
NANOFÁRMACOS
Departamento de Patentes e Información Tecnológica
Unidad de Información Tecnológica
NANOPARTICLE AGGREGATES CONTAINING OSTEOPONTIN AND CALCIUM- AND/OR STRONTIUM-CONTAINING
PARTICLES
Nº publicación EP2830647A1 04/02/2015
ARLA FOODS AMBA¿[DK]
Solicitantes
The present invention relates to nanoparticle aggregates comprising
Resumen
osteopontin (OPN) and one or more particles containing calcium
and/or strontium and to their use for reducing or preventing biofilm
growth or for removing biofilm. The invention furthermore relates to
the use of the nanoparticle aggregates for treating, alleviating or
preventing biofilm-related diseases.
DIETHER BASED BIODEGRADABLE CATIONIC LIPIDS FOR siRNA DELIVERY
Nº publicación EP2830594A1 04/02/2015
SIRNA THERAPEUTICS INC¿[US]
Solicitantes
Disclosed herein are novel cationic lipids that can be used in combination with other lipid components such as cholesterol and
Resumen
PEG-lipids to form lipid nanoparticles with oligonucleotides. The cationic lipids can demonstrate enhanced efficacy along with
lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic
lipids with one short lipid chain coupled with inclusion of hydrolysable functionality in the lipid chains to enhance the efficiency
and tolerability of in vivo delivery of siRNA.
Alertas Tecnológicas
- 19 de 31 -
NANOFÁRMACOS
Departamento de Patentes e Información Tecnológica
Unidad de Información Tecnológica
TRIGGER-RESPONSIVE CHAIN-SHATTERING POLYMERS
Nº publicación EP2831142A2 04/02/2015
UNIV ILLINOIS¿[US]
Solicitantes
Disclosed are polymers containing a backbone comprising alternating
Resumen
N-protected hydroxymethylaniline units ("spacer") and linker units.
Method to block site-specifically chemokine-related inflammatory processes in vascular diseases and metastasis
Nº publicación EP2832373A1 04/02/2015
EXPERIMENTELLE PHARMAKOLOGIE & ONKOLOGIE BERLIN BUCH¿[DE]
Solicitantes
INST OF CELLULAR BIOLOGY AND PATHOLOGY NICOLAE SIMINESCU¿[RO]
UNIV POLITEHNICA OF BUCHAREST¿[RO]
UNIV BONN¿[DE]
ISTANBUL UNIVERSITY¿[TR]
UNIV ZUERICH¿[CH]
The invention provides a method for blocking site-specifically chemokine-related inflammatory processes in vascular diseases
Resumen
and metastasis employing vascular targeted nanocarrier. In particular, the present invention provides two types of targeted n ano c
arrier (NC) with encapsulated c hemokine a ntagonists (CA) or c hemokine r eceptor a ntagonists (CRA): stabilised t
arget-sensitive l iposomes (TSL) and p olymeric n anoparticles (PNP). Both types of nanocarrier have attached on their surface
monoclonal antibodies or peptides that recognize VCAM-1 expressed on activated endothelial cells (EC). After binding of the
nanocarrier to the VCAM-1 expressed on EC, the encapsulated CA or CRA are released and will block the interaction between
chemokine and chemokine receptors. This will lead to an inhibition of transmigration of leukocytes (in atherosclerosis) or of
tumor metastatic cells (in cancer). The invention provides a carrier system which delivers effective concentrations of drugs
specifically to the diseased (target) sites and reduces the drug concentrations at non-target sites. This results in a reduced, even
absent, occurrence of side effects. The nanocarriers described in this invention have the potential to function as long-lasting
vehicles for delivering selectively CA or CRA to activated endothelium.
MAGNETIC NANOPARTICLES FOR THE APPLICATION IN HYPERTHERMIA, PREPARATION THEREOF AND USE IN
CONSTRUCTS HAVING A PHARMACOLOGICAL APPLICATION
Nº publicación BRPI0721148A2 03/02/2015
COLOROBBIA ITALIANA SPA¿[IT]
Solicitantes
There are described nanoparticles of magnetic metal oxides employable in constructs consisting in polymer particles possibly also
Resumen
incorporating pharmacologically active substances.
Alertas Tecnológicas
- 20 de 31 -
NANOFÁRMACOS
Departamento de Patentes e Información Tecnológica
Unidad de Información Tecnológica
MULTICOMPARTMENTAL LIPID NANOPARTICLES
Nº publicación FR3008900A1 30/01/2015
CENTRE NAT RECH SCIENT¿[FR]
Solicitantes
UNIV PARIS XI PARIS SUD¿[FR]
The present invention relates to novel multicompartmental lipid
Resumen
nanoparticles (or cellisomes) with excellent stability comprising a first
lipophilic compartment (lipid matrix) partly anchored to a second
hydrophilic compartment delimited by a phospholipid bilayer
(bilayer), as well as the method for preparing same and the use thereof
as a vector for administering a wide variety of molecules of interest.
COMPOSITIONS AND METHODS FOR ENHANCING PHYSIOLOGICAL PERFORMANCE AND RECOVERY TIME
Nº publicación NZ604063A 30/01/2015
REVALESIO CORP
Solicitantes
Provided are methods for enhancing exercise (e.g., intense, eccentric,
Resumen
elevated temperature, repetitive, aerobic, and high altitude)
performance, comprising administering electrokinetically-altered
aqueous fluids comprising an ionic aqueous solution of stably
configured charge-stabilized oxygen-containing nanostructures
predominantly having an average diameter of less than 100
nanometers. In certain aspects, enhancing exercise performance
comprises at least one of: reducing plasma inflammatory cytokines
(e.g.,
IFN-alpha,
ENA-78
and
BDNF)
ameliorating muscle/tendon damage or enhancing muscle/tendon
r e c o v e r y
reducing biomarkers of exercise-induced muscle injury (e.g., CK,
plasma
myoglobin)
ameliorating exercise induced tendinosis, tendonitis, tenosynovitis,
avulsion, and tendon strain associated with chronic repetitive
movement
or
enhancing
recovering
therefrom
increasing
VO2
max
decreasing
RPE
reducing
blood
lactate
preserving muscle contractile function (e.g., maximal force, joint
R
O
M
)
reducing
muscle
soreness
ameliorating onset of fatigue in an excercising subject. Improved
methods for producing electrokinetically altered aqueous fluids
(including sports beverages) are also provided.
Alertas Tecnológicas
- 21 de 31 -
NANOFÁRMACOS
Departamento de Patentes e Información Tecnológica
Unidad de Información Tecnológica
TREATMENT OF PANCREATIC CANCER WITH A COMBINATION OF A HYPOXIA-ACTI VATED PRODRUG AND A
TAXANE
Nº publicación WO2015013448A1 29/01/2015
THRESHOLD PHARMACEUTICALS INC¿[US]
Solicitantes
MERCK PATENT GMBH¿[DE]
Combined administration of a hypoxia-activated prodrug, such as TH-302, a taxane, such as nab-paclitaxel, and a nucleoside
Resumen
analog chemotherapeutic, such as gemcitabine, are efficacious in the treatment of cancer, including pancreatic cancer.
SPHERICAL NUCLEIC ACID-BASED CONSTRUCTS AS IMMUNOREGULATORY AGENTS
Nº publicación WO2015013675A1 29/01/2015
AURASENSE THERAPEUTICS LLC¿[US]
Solicitantes
Aspects of the invention relate to nanoscale constructs and related methods and compositions thereof. The compositions of the
Resumen
invention are useful for treating disorders that are sensitive to levels of immune cell activation, such as autoimmune disease or
other inflammation based disease or disorder.
NANOASSEMBLED COMPLEXES OF NUCLEIC ACIDS, AVIDIN AND BIOTINYLATED COMPOUNDS FOR USE AS
CARRIERS FOR INTRACELLULAR DELIVERY
Nº publicación WO2015011675A1 29/01/2015
ANANAS NANOTECH S R L¿[IT]
Solicitantes
It is herein described nanoassemblies of nucleic acids, avidin and biotinylated compounds for use as carriers for intracellular
Resumen
delivery. These nanoassemblies are composed of central nuclei of polyavidins, i.e. nuclei formed by a self- assembly of a plurality
of tetrameric units of avidin on nucleic acids, on which biotinylated compounds further self-assemble by means of the
high-affinity interactions between the avidin of the central nucleus and the biotin of the biotinylated compounds.
NANOPARTICLE PEG MODIFICATION WITH H-PHOSPHONATES
Nº publicación US2015030541A1 29/01/2015
MALLINCKRODT LLC¿[US]
Solicitantes
The present invention provides phosphonate conjugates and methods
Resumen
of preparing the phosphonate conjugates so as to allow, for example,
improved methods and compounds for modifying the surface of a
nanoparticle to increase in vivo circulation times and targeted delivery
performance.
Alertas Tecnológicas
- 22 de 31 -
NANOFÁRMACOS
Departamento de Patentes e Información Tecnológica
Unidad de Información Tecnológica
FORMULAS FOR DIAGNOSING AND TREATING HORMONE-DEPENDENT CANCERS AND CANCERS OF THE ORGANS
RESPONSIBLE FOR STEROID HORMONE SYNTHESIS
Nº publicación US2015030543A1 29/01/2015
COMMISSARIAT I EN ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES¿[FR]
Solicitantes
COMMISSARIAT L ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES¿[FR]
The present invention relates to a formula for a therapeutic agent or a diagnostic agent in the form of a nano-emulsion, a method
Resumen
for preparing said formula, and the use of this formula for treating or diagnosing hormone-dependent cancers and cancers of the
organs responsible for steroid hormone synthesis.
GLUCOSE-RESPONSIVE MICROGELS FOR CLOSED LOOP INSULIN DELIVERY
Nº publicación US2015030641A1 29/01/2015
MASSACHUSETTS INST TECHNOLOGY¿[US]
Solicitantes
Injectable insulin loaded microgels that are capable of modifying the
Resumen
amount of insulin released based on the patient's tissue glucose levels,
methods for making and using these compositions have been
developed. The microgels contain insulin, glucose oxidase entrapped
in or bound to the microgels, and an agent that reduces hydrogen
peroxide, entrapped in or bound to the microgels, wherein the
polymeric microgel expands when pH decreases from physiological
pH and shrinks when pH increases towards physiological pH, thereby
releasing insulin at a rate corresponding to the glucose concentration.
In one embodiment, the glucose oxidase and/or the agent reducing
hydrogen peroxide are encapsulated in nanogels, then encapsulated
within the microgel.
SELF-ASSEMBLED NANOSTRUCTURES
Nº publicación US2015031127A1 29/01/2015
STUPP SAMUEL I¿[US]
Solicitantes
RUFF YVES¿[US]
UNIV NORTHWESTERN¿[US]
The present disclosure is directed to the preparation of nanostructures
Resumen
by the encapsulation of a charged compound with individual
self-assembled unit nanostructures.
Alertas Tecnológicas
- 23 de 31 -
NANOFÁRMACOS
Departamento de Patentes e Información Tecnológica
Unidad de Información Tecnológica
AMPHIPHILIC DRUG-DRUG CONJUGATES FOR CANCER THERAPY, COMPOSITIONS AND METHODS OF
PREPARATION AND USES THEREOF
Nº publicación US2015031644A1 29/01/2015
UNIV SHANGHAI JIAOTONG¿[CN]
Solicitantes
The invention provides novel amphiphilic drug-drug conjugates useful as cancer therapeutics, and compositions and methods
Resumen
thereof.
METHOD FOR PREPARING NANO PARTICLES
Nº publicación US2015031707A1 29/01/2015
BIO SYNECTICS INC¿[KR]
Solicitantes
The present invention relates to a method for manufacturing nano-scale particles of an active material. More particularly, the
Resumen
present invention relates to a method which uniformly mixes a surfactant having an HLB value of 8 or more and a melting point
or glass transition temperature of 80 DEG C or lower and an active material, and mills the mixture using a roller mill, to thereby
prepare nano particle powder from the active material.
NANOCONJUGATES ABLE TO CROSS THE BLOOD-BRAIN BARRIER
Nº publicación US2015031745A1 29/01/2015
MIRKIN CHAD A¿[US]
Solicitantes
KO CAROLINE H¿[US]
STEGH ALEXANDER¿[US]
GILJOHANN DAVID A¿[US]
LUCIANO JANINA¿[US]
JENSEN SAMUEL A¿[US]
UNIV NORTHWESTERN¿[IL]
Polyvalent nanoconjugates address the critical challenges in
Resumen
therapeutic use. The single-entity, targeted therapeutic is able to cross
the blood-brain barrier (BBB) and is thus effective in the treatment of
central nervous system (CNS) disorders. Further, despite the
tremendously high cellular uptake of nanoconjugates, they exhibit no
toxicity in the cell types tested thus far. This property is critical for
therapeutic agent delivery applications for reducing off-target effects.
Alertas Tecnológicas
- 24 de 31 -
NANOFÁRMACOS
Departamento de Patentes e Información Tecnológica
Unidad de Información Tecnológica
CARRIER NANOPARTICLES AND RELATED COMPOSITIONS, METHODS AND SYSTEMS
Nº publicación US2015031832A1 29/01/2015
CALIFORNIA INST OF TECHN¿[US]
Solicitantes
Carrier nanoparticles comprising a polymer containing a polyol
Resumen
coupled to a polymer containing a boronic acid, configured to present
the polymer containing a boronic acid to an environment external to
the nanoparticle and related compositions, methods and systems.
Alertas Tecnológicas
- 25 de 31 -
NANOFÁRMACOS
Departamento de Patentes e Información Tecnológica
Unidad de Información Tecnológica
FIBRIN HYDROGELS COMPRISING PLASMONIC NANOPARTICLES
Nº publicación ES2527800A1 29/01/2015
FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO LA PAZ FIBHULP¿[ES]
Solicitantes
CT DE INVESTIGACION BIOMEDICA EN RED EN BIOINGENIERIA BIOMATERIALES Y NANOMEDICINA CIBER
BBN¿[ES]
UNIV ZARAGOZA¿[ES]
The invention relates to a photothermal composition comprising a
Resumen
fibrin hydrogel matrix or a mixture of the precursors thereof, thrombin
and fibrinogen, in which hydrogel plasmonic nanoparticles and
heat-sensitive effectors are embedded, said effectors containing
therapeutic agents that are released by applying electromagnetic
radiation of a determined intensity and wavelength to the composition.
The photothermal composition is suitable for generating hyperthermia
in biological tissues in which said composition is implanted. The
invention therefore also relates to the use of the composition for the
destruction of tumours, the treatment of infections or the regeneration
of tissues, as well as for the controlled administration of therapeutic
agents.
NANOEMULSIONS OF HYDROPHOBIC PLATINUM DERIVATIVE
Nº publicación WO2015013566A1 29/01/2015
NEMUCORE MEDICAL INNOVATIONS INC¿[US]
Solicitantes
GANTA SRINIVAS¿[US]
COLEMAN TIMOTHY P¿[US]
Provided are nanoemulsion formulations useful for the delivery of hydrophobic platinum chemotherapeutic drugs to cancer
Resumen
patients, as well as methods of their preparation and use.
COMPOSITIONS AND METHODS FOR UPREGULATING HIPPOCAMPAL PLASTICITY AND HIPPOCAMPUS-DEPENDENT
LEARNING AND MEMORY
Nº publicación WO2015013451A2 29/01/2015
REVALESIO CORP¿[US]
Solicitantes
Provided are methods for enhancing hippocampal plasticity and hippocampal-mediated learning and memory, and/or enhancing
Resumen
the synaptic maturation of neurons, and/or optimizing or enhancing neuronal synaptic transmission, and/or enhancing intracellular
oxygen delivery or utilization, and/or enhancing ATP synthesis, comprising administration, to a subject in need thereof of a
sufficient amount over a sufficient time, of an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures (e.g.,
nanobubbles) having an average diameter of less than 100 nm (e.g., in at least one subject group selected from but not limited to
normal subjects, subjects recovering from neurological trauma (e.g., accidents or injury to the brain, stroke, oxygen deprivation,
drowning, and asphyxia), and subjects with learning disorders (e.g., dyslexia, dyscalculia, dysgraphia, dyspraxia (sensory
integration disorder), dysphasia/aphasia, auditory processing disorder, non-verbal learning disorder, visual processing disorder,
and attention deficit disorder (ADD)).
Alertas Tecnológicas
- 26 de 31 -
NANOFÁRMACOS
Departamento de Patentes e Información Tecnológica
Unidad de Información Tecnológica
MULTICOMPARTMENTAL LIPID NANOPARTICLES
Nº publicación WO2015011419A1 29/01/2015
CENTRE NAT RECH SCIENT¿[FR]
Solicitantes
UNIVERSITÉ DE PARIS XI PARIS SUD¿[FR]
The present invention relates to novel multicompartmental lipid
Resumen
nanoparticles (or cellisomes) with excellent stability comprising a first
lipophilic compartment (lipid matrix) partly anchored to a second
hydrophilic compartment delimited by a phospholipid bilayer
(bilayer), as well as the method for preparing same and the use thereof
as a vector for administering a wide variety of molecules of interest.
METHOD FOR OBTAINING A NANO-CAPSULE STRUCTURE
Nº publicación IL235959A 29/01/2015
CENTRE NAT RECH SCIENT
Solicitantes
UNIV LORRAINE
MC MURTY STEFAN
ELMAZRIA OMAR
The present invention concerns a method for obtaining a nano-capsule
Resumen
(4) structure (S) comprising at least one capsule (4) nanometric in size
capable of enabling the encapsulation a compound, in which: - at least
one layer of resin (5) is deposited on a layer of substrate (6)
- said layer of resin (5) is structured, by low voltage electron
lithography, or by optical lithography or by nanoimprinting in such a
way as to obtain at least one cavity (7) in the thickness of said layer of
resin (5), said cavity (7) having a depth p smaller than the thickness E
of
said
layer
of
resin
(5)
- at least one layer of an encapsulating material (8) is isotropically
deposited by sputtering said material (8) under vacuum
- the cavity or cavities (7) are sealed with a sealing material (10)
- the layer of resin (5) is dissolved by soaking in a suitable solvent.
Potato protein nanoparticles
Nº publicación IL228528A 29/01/2015
TECHNION RES & DEV FOUNDATION¿[IL]
Solicitantes
LIVNE YOAV¿[IL]
Alertas Tecnológicas
- 27 de 31 -
NANOFÁRMACOS
Departamento de Patentes e Información Tecnológica
Unidad de Información Tecnológica
MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS
Nº publicación JP2015502946A 29/01/2015
The present invention relates to targeted delivery compositions
Resumen
comprising matrix metalloproteinase (MMP) inhibitors and methods
of using the compositions for treating and diagnosing a disease state in
a subject.
REGULAR HEXAHEDRAL OR OCTAHEDRAL FERRITE NANOPARTICLE, AND METHOD FOR PRODUCING SAME
Nº publicación JP2015017036A 29/01/2015
The present invention relates to cubic or octahedral ferrite
Resumen
nanoparticles and a method for preparing the same. In particular, the
present invention is directed to a ferrite nanocube which is
superparamagnetic or ferromagnetic, and a method for preparing a
ferrite nanocube, comprising heating a mixture of a metal precursor, a
surfactant and a solvent.
Alertas Tecnológicas
- 28 de 31 -
NANOFÁRMACOS
Departamento de Patentes e Información Tecnológica
Unidad de Información Tecnológica
EXOPOLYSACCHARIDE FOR THE TREATMENT AND/OR CARE OF THE SKIN, MUCOUS MEMBRANES AND/OR NAILS
Nº publicación EP2827837A2 28/01/2015
LUBRIZOL ADVANCED MAT INC¿[US]
Solicitantes
POLYMARIS BIOTECHNOLOGY¿[FR]
Exopolysaccharide of a bacterial strain for its use in treatment and/or care of the skin, mucous membranes, hair and/or nails, as
Resumen
well as its cosmetic and/or dermopharmaceutical compositions. In particular, for the aging of skin and in particular for the
treatment and/or prevention of wrinkles.
DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE
TRANSFER IN VIVO
Nº publicación EP2828332A1 28/01/2015
ENGENE INC¿[CA]
Solicitantes
Provided herein is chitosan dually derivatized with arginine and
Resumen
g l u c o n i c
a c i d
and methods of making and using the same, e.g., for gene delivery in
vivo.
Alertas Tecnológicas
- 29 de 31 -
NANOFÁRMACOS
Departamento de Patentes e Información Tecnológica
Unidad de Información Tecnológica
NANOASSEMBLED COMPLEXES OF NUCLEIC ACIDS, AVIDIN AND BIOTINYLATED COMPOUNDS FOR USE AS
CARRIERS FOR INTRACELLULAR DELIVERY
Nº publicación ITPD20130210A1 27/01/2015
ANANAS NANOTECH S R L
Solicitantes
It is herein described nanoassemblies of nucleic acids, avidin and
Resumen
biotinylated compounds for use as carriers for intracellular delivery.
These nanoassemblies are composed of central nuclei of polyavidins,
i.e. nuclei formed by a self- assembly of a plurality of tetrameric units
of avidin on nucleic acids, on which biotinylated compounds further
self-assemble by means of the high-affinity interactions between the
avidin of the central nucleus and the biotin of the biotinylated
compounds.
Alertas Tecnológicas
- 30 de 31 -
NANOFÁRMACOS
Departamento de Patentes e Información Tecnológica
Unidad de Información Tecnológica
POLYMERISED CERIUM OXIDE NANOPARTICLES IN AN ACTIVE OR BIOACTIVE NETWORK, PROTECTIVE TOPICAL
TREATMENTS, METHODS FOR PREPARATION THEREOF AND USES THEREOF
Nº publicación FR3008700A1 23/01/2015
UNIV NICE SOPHIA ANTIPOLIS¿[FR]
Solicitantes
CENTRE NAT RECH SCIENT¿[FR]
The invention concerns a compound formed by functionalized microResumen
or nanoparticles associated covalently with rheology-modifying
polymers. The invention is characterized in that the functionalized
micro- or nanoparticles are functionalized micro- or nanoparticles of
cerium oxide (CeO2) having a nominal diameter of between 1 and
1500 nm. The rheology-adapting or -modifying polymers are selected
from among non-associative or associative polymers. The invention is
used in skin protection or decontamination.
Alertas Tecnológicas
- 31 de 31 -
NANOFÁRMACOS